

AMENDMENTS TO THE CLAIMS

1-12 (Cancelled)

13. (Currently Amended) A process for producing a composition for the treatment of a disease, condition or disorder, comprising:

contacting blood or a fraction thereof with a therapeutic substance selected from the group consisting of tetracyclines or tetracycline-like compounds thereby increasing the level of cytokine receptors in the blood or the fraction thereof; and

*OK to ENTER!  
5/1/06  
yc*  
after the contacting, isolating the blood or the fraction thereof having the increased cytokine receptors.

14. (Previously Presented) The process of Claim 13, wherein the contacting is in vivo.

15. (Previously Presented) The process of Claim 13, wherein the contacting is in vitro.

16. (Previously Presented) The process of Claim 13, wherein the cytokine receptors are increased at least three-fold relative to non-contacted blood or a fraction thereof.

17. (Previously Presented) The process of Claim 13, wherein the cytokine receptors are selected from the group consisting of interleukin-1 receptors and tumor necrosis factor receptors.

18. (Previously Presented) The process of Claim 13, further comprising processing the isolated blood or fraction thereof by a process selected from the group consisting of: centrifugation, filtration, fractional precipitation, organic solvent precipitation, selective absorption, isoelectric precipitation, and chromatography.

19. (Previously Presented) The process of Claim 18, wherein the blood or fraction thereof includes a gamma-globulin fraction, a anti-hemophilia factor fraction, a albumin fraction, serum and plasma.

20. (Previously Presented) The process of Claim 13, wherein the disease, condition or disorder includes viral hemorrhagic diseases, sepsis, cachexia, rheumatoid arthritis, acute